Company news
Janux Therapeutics, Inc. (NASDAQ:JANX) news
Every Janux Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
September 14, 2026
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 6, 2026
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 27, 2026
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
April 16, 2026
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone ...
April 1, 2026
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
February 17, 2026
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
January 26, 2026
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-A...
January 22, 2026
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
December 23, 2025
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
December 1, 2025
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
November 24, 2025
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 6, 2025
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 7, 2025
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
August 5, 2025
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtu...
July 24, 2025
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
July 17, 2025
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
May 15, 2025
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
May 8, 2025
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
May 5, 2025
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
January 24, 2025
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of U...
December 6, 2024
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 4, 2024
Janux Therapeutics Announces Proposed Public Offering
December 3, 2024
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Do...
December 2, 2024
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Sele...
November 25, 2024
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 6, 2024
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 7, 2024
Janux Therapeutics Announces Updates to Board of Directors
July 22, 2024
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 7, 2024
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 8, 2024
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
February 29, 2024
Janux Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2024
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-...
February 26, 2024
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
February 20, 2024
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
January 8, 2024
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 7, 2023
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 8, 2023
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeli...
July 17, 2023
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
July 17, 2023
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
June 5, 2023
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 9, 2023
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
April 24, 2023
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
April 20, 2023
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 10, 2023
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
February 14, 2023
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
December 27, 2022
Janux Therapeutics to Present at Upcoming Investor Conferences in November
November 22, 2022